TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1970633
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g DS implant
Study: 1970633
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) implants
Study: 393242
Drug: Transdermal therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapeutic system scopolamine (TTS-scopolamine)
Study: 393242
Drug: Oral dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dimenhydrinate
Study: 31048871
Drug: Paromomycin-gentamicin topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin-gentamicin topical cream
Study: 31048871
Drug: Paromomycin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin alone topical cream
Study: 18781486
Drug: Soy (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy (52 g of soy protein containing 112 mg of isoflavones)
Study: 12904084
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with dendritic cells
Study: 11214425
Drug: Epoetin-alpha 10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha 10,000 UI twice a week and 525 mg ferrous sulphate 3 times a day
Study: 11214425
Drug: 525 mg
Normalized name: psyllium 525 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 525 mg ferrous sulphate three times a day per os for 3 weeks
Study: 9414541
Drug: Radical treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical treatments (radical prostatectomy, radical radiotherapy)
Study: 9414541
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management (monitoring and treatment of symptoms)
Study: 8017473
Drug: Fluvastatin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 10 to 40 mg/day
Study: 2783678
Drug: Endoscopic sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sclerotherapy plus oral propranolol
Study: 2783678
Drug: Transhepatic sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transhepatic sclerotherapy plus oral propranolol
Study: 781848
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate ointment; treated with active drug for three weeks
Study: 23819224
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy (qi pathway intervention and spinal adjustment)
Study: 23819224
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (acupuncture and Tuina)
Study: 22568666
Drug: Alkaline formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline formulation of human albumin (pH 10)
Study: 22568666
Drug: Neutral formulation
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral formulation of human albumin (pH 7.4)
Study: 22568666
Drug: All injections
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All injections (both formulations)
Study: 15969309
Drug: Intranasal phototherapy
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal phototherapy (3 times a week for 3 weeks)
Study: 12028307
Drug: Control teeth
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control teeth (not exposed to demineralizing solution)
Study: 9809500
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide aqueous suspension (256 microg once daily)
Study: 9809500
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride nasal spray (280 microg twice daily)
Study: 7695326
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.5 mg/kg of body weight per day)
Study: 28804009
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein drink (30 g/120 kcal, 140 mL) consumed 3 hours before a buffet meal
Study: 28804009
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein drink (30 g/120 kcal, 140 mL) consumed 2 hours before a buffet meal
Study: 28804009
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein drink (30 g/120 kcal, 140 mL) consumed 1 hour before a buffet meal
Study: 28804009
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein drink (30 g/120 kcal, 140 mL) consumed immediately before a buffet meal
Study: 15321026
Drug: Latanoprost once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost once-weekly
Study: 15321026
Drug: Latanoprost once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost once-daily (control)
Study: 12575552
Drug: Lingjiao Jiangya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingjiao Jiangya Pill
Study: 8162926
Drug: Dexamethasone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.1 mg)
Study: 31179316
Drug: Not practicing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not practicing at least 30 min daily walks
Study: 23683134
Drug: Allopurinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (200 mg or 300 mg)
Study: 17997711
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate 2 g/d orally for 3 years
Study: 8900554
Drug: Misoprostol in
Normalized name: Product containing misoprostol in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol in patients requiring concomitant antacid use
Study: 1800188
Drug: Celandin-aloevera-psyllium preparation
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celandin-aloevera-psyllium preparation
Study: 31971679
Drug: Teprotumumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for subsequent infusions, administered intravenously every 3 weeks for 21 weeks)
Study: 26847728
Drug: D-glucose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-glucose (10 mmol L(-1))
Study: 22431338
Drug: Riluzole treatment
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole treatment for 1 week
Study: 20094001
Drug: weblink to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: weblink to CDC sexually transmitted disease treatment guidelines
Study: 15595937
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) therapy after placebo delay
Study: 10588611
Drug: Inhaled allergen
Normalized name: Inhaled allergen mix specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled allergen challenge
Study: 10588611
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids pretreatment
Study: 2108408
Drug: L-649,923 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-649,923 (oral LTD4 antagonist)
Study: 6765920
Drug: Timolol (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (10-30 mg twice daily)
Study: 28403379
Drug: Resveratrol 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 125 mg/d
Study: 28403379
Drug: Resveratrol 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 500 mg/d
Study: 26044566
Drug: probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: probucol 500 mg/day
Study: 26044566
Drug: aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 100 mg/day
Study: 16781624
Drug: Engystol-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engystol-based therapy
Study: 16781624
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies (antihistamines, antitussives, NSAIDs)
Study: 10722768
Drug: Ipratropium 40
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 40 microg four times daily
Study: 27983686
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg polyphenols derived from red wine and grape extracts in protein-rich beverages (dairy, soy)
Study: 27983686
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg polyphenols derived from red wine and grape extracts in protein-free beverage
Study: 27983686
Drug: Placebo (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (six gelatine capsules)
Study: 18285548
Drug: Maribavir 400
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 400 mg once daily
Study: 15624040
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg/day (n = 30)
Study: 29153754
Drug: Combined activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined activity program (90-minute sessions weekly for 40 weeks)
Study: 21876572
Drug: 0.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/kg of 0.25 % bupivacaine with 1 mg/kg of tramadol (Group B)
Study: 21876572
Drug: 0.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/kg of 0.25 % bupivacaine (Group A)
Study: 16731091
Drug: Infected black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infected black women who received CDC recommended treatment
Study: 11049909
Drug: Atropine 5
Normalized name: Isopto Homatropine 5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 5 microg/kg (small-dose)
Study: 11049909
Drug: Atropine 10
Normalized name: Isopto Atropine 10 MG/ML Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 10 microg/kg (large-dose)
Study: 8615503
Drug: Tizanidine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine 12 mg
Study: 1397667
Drug: Vivida (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vivida (500 mg/day for 90 days)
Study: 1397667
Drug: Imedeen (380
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imedeen (380 mg/day for 90 days)
Study: 26996246
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS up-titration from 30 mg to 60 mg
Study: 26996246
Drug: Valsartan up-titration
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan up-titration from 80 mg to 160 mg
Study: 26996246
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination of Nifedipine GITS (30 mg) and Valsartan (80 mg)
Study: 26996246
Drug: Low-dose monotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monotherapy of Nifedipine GITS (30 mg)
Study: 26996246
Drug: Low-dose monotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monotherapy of Valsartan (80 mg)
Study: 25275672
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 mg, oral, twice daily, titrated over 2 weeks)
Study: 22527079
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 μg/kg/min continuous infusion for 72 hours)
Study: 22527079
Drug: Standard post‐CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post‐CPB inotrope infusion
Study: 10373872
Drug: Questionnaire administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questionnaire administered on the second postnatal day
Study: 2201759
Drug: Subgingival irrigation
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival irrigation with 0.12% CHX and daily marginal irrigation with 0.04% CHX
Study: 2201759
Drug: Subgingival irrigation
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival irrigation with 0.12% CHX and daily marginal irrigation with water
Study: 2201759
Drug: Subgingival and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival and daily marginal irrigation with water
Study: 31713774
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (Se) treatment at 50 to 200 nmol/L
Study: 31713774
Drug: LPS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS treatment (only LPS)
Study: 31713774
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (Se) treatment with LPS (LS50 to LS200)
Study: 31713774
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (Se) treatment at 50 to 100 nmol/L
Study: 30231899
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (Se) treatment
Study: 28407007
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily (Arm A)
Study: 28407007
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, each twice daily) plus polaprezinc 150 mg twice daily (Arm B)
Study: 28407007
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy alone (Arm C)
Study: 28407007
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B (Triple therapy plus polaprezinc 150 mg)
Study: 26286610
Drug: 0.1% Mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Mometasone Furoate Cream (MF) in combination with LA-Cer moisturizer
Study: 26286610
Drug: 0.1% Mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Mometasone Furoate Cream (MF)
Study: 11094038
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of prostacyclin in 15 patients with PPH and 3 with sPAH.
Study: 8659199
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg/day
Study: 1644341
Drug: Nasal oxygen
Normalized name: TUBE,NASAL OXYGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal oxygen supplementation (2 l/min)
Study: 6240785
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G (4.8 X 10(6) units im) plus probenecid (1 g perorally)
Study: 6240785
Drug: Spectinomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin (2 g im)
Study: 26813849
Drug: 60 once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 once-daily pills after each donation (19 mg of iron)
Study: 26813849
Drug: 60 once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 once-daily pills after each donation (38 mg of iron)
Study: 25664051
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D oral supplementation (45000 IU/week for 2 months and a single 45000 IU in the last month)
Study: 18410902
Drug: Intravenous busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous busulfan 130 mg/m(2) once daily x 4 days and fludarabine 40 mg/m(2) daily x 4 days
Study: 12429757
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Sequential transection of the triangular fibrocartilage complex and the interosseous membrane
Study: 12429757
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Sequential transection of the interosseous membrane and the triangular fibrocartilage complex
Study: 10339471
Drug: Prophylactic inhalations
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic inhalations with aerosolized amphotericin B (aeroAmB) at a dose of 10 mg twice daily
Study: 10339471
Drug: No inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhalation prophylaxis
Study: 7499945
Drug: Beclomethasone nasal
Normalized name: beclomethasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone nasal spray (Beconase) applied to one nostril for six weeks
Study: 1959515
Drug: Dutch dietary
Normalized name: ditch stonecroft extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutch dietary guidelines diet (G)
Study: 31099485
Drug: MTX therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX therapy
Study: 31099485
Drug: MTX cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX cumulative dose
Study: 31099485
Drug: MTX treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX treatment duration
Study: 25431865
Drug: L-DNR/FLAG (liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DNR/FLAG (liposomal daunorubicin, fludarabine, cytarabine, G-CSF)
Study: 25431865
Drug: L-DNR/FLAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-DNR/FLAG
Study: 15676064
Drug: Full vacuum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full vacuum suction drainage (pressure = 700 g/m2)
Study: 15676064
Drug: Half vacuum
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half vacuum suction drainage (pressure = 350 g/m2)
Study: 6986242
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets twice daily)
Study: 30793177
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 3 (250,000 IU single dose followed by 50,000 IU every other week)
Study: 30793177
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically matched placebo pill)
Study: 26159020
Drug: CHSQABC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHSQABC + routine Western medicine treatment (Xinyue Capsule: 2 pills, 3 times/day; Compound Chuanxiong Capsule: 2 pills, 3 times/day for half a year)
Study: 26159020
Drug: Routine Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Western medicine treatment (control group)
Study: 26159020
Drug: CHSQABC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHSQABC + routine Western medicine treatment
Study: 20415263
Drug: Cycloferon (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloferon (exact dosage not specified)
Study: 6356326
Drug: Gastrointestinal hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastrointestinal hormones (VIP, motilin, enteroglucagon)
Study: 31727580
Drug: Algorithm-guided empirical
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-guided empirical tuberculosis treatment
Study: 25273547
Drug: Lactobacillus paracasei
Normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus paracasei subsp. paracasei L. casei W8® (1010 cfu daily) for four weeks
Study: 23783097
Drug: CDCA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA (5 mmol/L)
Study: 23783097
Drug: CDCA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA (15 mmol/L)
Study: 23783097
Drug: CDCA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDCA (5 or 15 mmol/L)
Study: 23783097
Drug: Sodium oleate
Normalized name: sodium oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium oleate with 5 mmol/L CDCA
Study: 19173181
Drug: (90)Y‐DOTATATE (7.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y‐DOTATATE (7.4 GBq/m(2) cumulative dose)
Study: 19173181
Drug: (90)Y‐ibritumomab tiuxetan
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y‐ibritumomab tiuxetan (1200 MBq max dose)
Study: 9372504
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose (TD) gadolinium (0.3 mmol/kg)
Study: 9372504
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (s.d.) gadolinium (0.1 mmol/kg)
Study: 29559344
Drug: Ustekinumab treatment
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab treatment
Study: 27475688
Drug: Oral ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketorolac 10 mg plus intramuscular placebo (1 mL saline solution)
Study: 27475688
Drug: Intramuscular tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tramadol 50 mg diluted in 1 mL saline solution plus oral placebo (similar tablet to oral ketorolac)
Study: 24047817
Drug: Tetravalent vaccine
Normalized name: DENGUE TETRAVALENT VACCINE,LIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent vaccine and placebo
Study: 24047817
Drug: A/H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/H5N1 vaccine and placebo
Study: 24047817
Drug: A/H5N1 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/H5N1 and seasonal vaccines
Study: 23368891
Drug: Conventional cannulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cannulation (CC)
Study: 23368891
Drug: Accidental guidewire
Normalized name: Anacardium occidentale whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accidental guidewire insertions and unintended injections of contrast into the main pancreatic duct
Study: 18793563
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional oral agents alone)
Study: 1586733
Drug: Prophylactic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic heparin 100 U/kg/d by continuous infusion from day -8 until day +30 post-BMT